Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.38 |
| ▸ | KLK7 | P49862 | 7/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ASPH | Q12797 | 2/20 | 0.35 |
| ▸ | RIOX2 | Q8IUF8 | 2/20 | 0.35 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765503 | 0.90 | BCHE (0.41) | BCHEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL31558528 | 0.89 | BCHE (0.40) | BCHEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30765476 | 0.88 | ELANE (0.40) | BCHEKLK7KLK5KDM4EALDH1A1 | |
| SCHEMBL30765744 | 0.88 | BCHE (0.38) | BCHEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30766052 | 0.81 | KLK7 (0.42) | BCHEKLK7KLK5 | |
| SCHEMBL30765946 | 0.79 | F2 (0.39) | BCHEF2KDM6BKDM4C | |
| SCHEMBL30765978 | 0.79 | ELANE (0.41) | BCHEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30765994 | 0.77 | ELANE (0.46) | KDM4EASPHRIOX2KDM8ALDH1A1 | |
| SCHEMBL30765644 | 0.77 | KDM4E (0.42) | KDM4EASPHRIOX2KDM8ALDH1A1 | |
| SCHEMBL30765914 | 0.76 | ELANE (0.39) | KDM4EASPHRIOX2KDM8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |